Seattle Genetics and Collaborators Will Present Data from Multiple Antibody-Drug Conjugate (ADC) Programs at ASCO Annual Meeting

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. SGEN today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL.

With over 16 years of experience and knowledge in ADC innovation, Seattle Genetics is the leader in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Of the more than 30 ADC candidates in clinical development, greater than 20 utilize Seattle Genetics' proprietary ADC technology. Seattle Genetics and its collaborators, including Genentech (a member of the Roche Group), AbbVie and Progenics, have nine data presentations at ASCO that highlight the widespread evaluation of its ADC technology to potentially impact the way cancer is treated.

Corporate and collaborator presentations are included below and full abstracts can be accessed on the ASCO website at abstracts.asco.org.

Friday, May 30, 2014

• A phase 1 study evaluating ABT-414 in combination with temozolomide for subjects with recurrent or unresectable glioblastoma (AbbVie; Abstract #2021, poster presentation)
• A phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer (Genentech; Abstract #2529, poster presentation)

Saturday, May 31, 2014

• Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (Genentech; Abstract #8519, oral presentation 1:39 p.m. Central Time [CT])
• A phase I study of DNIB0600A, an antibody-drug conjugate targeting NaPi2b, in patients with non-small cell lung cancer or platinum-resistant ovarian cancer (Genentech; Abstract #2504, oral presentation 2:27 p.m. CT)
• A phase I study of DSTP3086S, an antibody-drug conjugate targeting STEAP-1, in patients with metastatic castration-resistant prostate cancer (Genentech; Abstract #5024, poster presentation)
• A phase 2 trial of prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (Progenics; Abstract #5023, poster presentation)

Sunday, June 1, 2014

• Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (Seattle Genetics; Abstract #8505, oral presentation 9:48 a.m. CT)

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS^® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available for two indications in 40 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage ADC programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME and ASG-15ME. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.